TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ValiRx plc ( (GB:VAL) ) has provided an announcement.
ValiRx plc announced the successful passing of all resolutions at its recent General Meeting, paving the way for the issuance of new equity and warrants as part of its fundraising efforts. The company plans to admit 256,067,800 new shares to trading on AIM, with the issuance of 368,372,400 fundraising warrants and 16,036,120 broker warrants, which are exercisable until the third anniversary of the admission. This strategic move is expected to bolster ValiRx’s financial position, enabling further investment in its pipeline of cancer therapeutics and women’s health products, potentially enhancing its market position and delivering value to stakeholders.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
Spark’s Take on GB:VAL Stock
According to Spark, TipRanks’ AI Analyst, GB:VAL is a Underperform.
ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, marked by significant losses and reliance on external financing. The technical analysis indicates bearish trends, with the stock being oversold. Valuation metrics are unfavorable due to negative earnings and lack of dividends. These factors collectively suggest a high-risk investment profile.
To see Spark’s full report on GB:VAL stock, click here.
More about ValiRx plc
ValiRx is a life sciences company that specializes in early-stage cancer therapeutics and women’s health. It focuses on accelerating the translation of innovative science into impactful medicines to improve patient lives. The company provides a framework for the rapid development of novel drug candidates, guiding them from pre-clinical studies to investor-ready assets. ValiRx collaborates with various experts to streamline and reduce the cost of drug development, with lead candidates being outlicensed or partnered for further development and commercialization.
Average Trading Volume: 2,957,191
Technical Sentiment Signal: Sell
Current Market Cap: £1.14M
For a thorough assessment of VAL stock, go to TipRanks’ Stock Analysis page.